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Abstract
Background: Global collaboration in genomic research is increasingly both a scientific reality and an ethical imperative.
This past decade has witnessed the emergence of six new, interconnected areas of ethical consensus and emphasis for
policy in genomics: governance, security, empowerment, transparency, the right not to know, and globalization.
Discussion: The globalization of genomic research warrants an approach to governance policies grounded in human rights.
Summary: A human rights approach activates the ethical principles underpinning genomic research. It lends
force to the right of all citizens to benefit from scientific progress, and to the right of all scientists to be
recognized for their contributions.
Background
In 1994, the authors of this text exposed what they ana-
lyzed to be the ethical and legal norms underlying the
Human Genome project from December 1989 to July
1994 [1]. We found several areas of international consen-
sus centered on autonomy; privacy; justice; equity; and,
equality, which out of respect for human dignity “could
serve to harmonize eventual national regulation” pg. 2035.
We considered it urgent to have some codification in
an international instrument and hoped that UNESCO
would lead in this direction. In 1997, UNESCO adopted
its Universal Declaration on the Human Genome and
Human Rights [2].
We revisited these principles two years after the publica-
tion of the sequence map of the human genome in 2005.
While still prominent, the principles were complemented
by more social and communal concerns and trends in eth-
ics that we identified as: reciprocity; mutuality; solidarity;
citizenry; and, universality [3]. We concluded that “ethics
does not consist of a static set of theories or principles
that can be unproblematically ‘applied’ to new situations”
pg.77, and that “[t]here might not, and cannot, be universal
norms in bioethics, as emerging ethical norms are as
‘epigenetic’ as the science they circumscribe” pg.78.
A decade later, we again attempt to discern movement
in international ethical norms. We posit that another six
areas of complementary ethical consensus and emphasis
have either emerged or moved to centre stage. They are:
governance; security; empowerment; transparency; the
right not to know; and, globalization. Two points need
to be emphasized. First, these areas are not independent
but rather intertwined. Empowerment and transparency,
for example, are clearly connected. Second, the areas of
ethical interest here are not specific to genomics only.
Issues of security, most obviously, are at stake in a num-
ber of different contexts, and in some cases it is helpful
to have regard for those contexts to further illuminate
what is happening in genome-ethics. These developments
inspired the adoption of a human rights approach mani-
fest in the Framework for Responsible Sharing of Genomic
and Health-Related Data (Framework) [4] of the Global
Alliance for Genomics & Health (GA4GH) [5]. It is import-
ant to note that the Framework adopted such an approach
due to the more universal and actionable character of
human rights. Calling on article 27 of the Universal
Declaration of Human Rights [6] and article 15 of the
binding International Covenant on Economic, Social and
Cultural Rights [7], the latter signed and ratified by 164
countries, the Framework envisages responsible data shar-
ing founded on the right of all citizens to benefit from sci-
ence, and the right to be recognized for one’s intellectual
contribution.
What does a global momentum centered on activating
these human rights reveal about the evolving international
ethics landscape? The following sections describe how six
areas of consensus are informing policies of genomic gov-
ernance in this regard.* Correspondence: bartha.knoppers@mcgill.ca1Centre of Genomics and Policy, McGill University, 740 Ave Dr. Penfield Suite
5200, Montreal, QC, H3A 0G1, Canada
Full list of author information is available at the end of the article
© 2015 Knoppers and Chadwick. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Knoppers and Chadwick BMC Medical Ethics  (2015) 16:58 
DOI 10.1186/s12910-015-0054-4
Discussion
Governance
Gottweis et al. defined governance as “[a] multifaceted
compound situation of institutions, systems, structures,
processes, procedures, practices, relationships and lead-
ership behaviour in the exercise of social, political, eco-
nomic, and managerial/administrative authority in the
running of public or private affairs” [8]. Governance can
further include professional guidelines in addition to pro-
cedures and practices. It has, to some degree, become an
umbrella term for different ways of ensuring that the
interests of affected parties are appropriately safeguarded.
The emergence of biobanks attests to the impractical-
ities of obtaining individual consent for every future use
of stored data and samples. Nowhere is the gradual shift
in emphasis from individual consent to governance bet-
ter illustrated than in the adoption by the United States
National Institutes of Health (NIH) of its Genomic Data
Sharing (GDS) Policy on August 27th, 2014 [9]. The
GDS Policy expects researchers to: “seek consent from
participants for future research uses and the broadest
possible sharing”; deposit such data in NIH designated
repositories; and use Trusted Partners via contractual
mechanisms for storage or for analytical tools. The NIH
provides elaborate guidance as well as the creation of
DACs (Data Access Committees) with a notification sys-
tem for any alleged misuse or mismanagement. More-
over, “secondary users in violation of the Policy or the
Data Use Certification may face enforcement actions”.
De-identified data for the NIH will now be considered
controlled data, and users must be approved by a DAC.
Controlled access illustrates an approach to governance
already tried and tested in international consortia such
as the International Cancer Genome Consortium (ICGC)
[10]. Data in open repositories such as the 1000 Genomes
Project continue to be publicly available, however these
are not individual level data [11]. Under the GDS, appro-
priate governance with oversight lines of accountability
and sanctions counterbalance the trust of participants
who provide broad consent for future unspecified research
uses of their data and samples.
Security
While privacy remains a primary concern for the use
of genetic or genomic data—especially now that re-
identifiability of previously anonymized participants
cannot be ruled out [12, 13] with the arrival of Big
Data—the locus of privacy protection is shifting to
security. In essence, security is the state of being free
from danger or threat and is a concept that applies in
a number of fields. Food security relates to the availability
of a sustainable food supply; airport security deals with
threats to safety among travelers and personnel. The cen-
tral issue in the context of data security is preventing
unauthorized access, which includes but goes beyond indi-
vidual privacy concerns.
The challenges arising from technological change have
led some to portray the situation we currently face as a
trade-off between privacy and security, but the situation
is more complicated than that. There is a public (and not
only an individual or group) interest in privacy as well as
security, and security itself may be necessary to safeguard
this public interest.
The security issues pertaining to personal data present
some of the most complex challenges of the current dec-
ade. Concerns over the security of personal data, particu-
larly in Europe following the National Security Agency
scandal, and together with ever- increasing cloud comput-
ing for large datasets, make data security a priority [14].
The travails and tribulations of the proposed European
Data Protection Regulation [15] attest to the concerns of
policymakers and the public about unauthorized access to,
and use of sensitive data. The proposed stringent protec-
tion of sensitive data has led to much discussion in Europe
over the need to create exemptions for research using
health data (including genetic data) [16]. Safe havens for
data deposit and use have been proposed as part of secur-
ity with the following common attributes: data mainten-
ance and release must be socially acceptable and
appropriate, data must be veritable, and data must be safe
and secure [17].
Empowerment
In 2005, we described the growing trend to incorporate
public consultation, engagement or involvement in
research under the rubric of “citizenry”. While a ubiquitous
phenomenon, engagement is not necessarily a panacea. In
light of noticeable moves toward evaluating engagement
activities, what difference do they actually make to policy?
Today, empowerment of individuals goes beyond in-
stitutionalizing strategies for including the public. The
mechanisms of public engagement have undergone a
series of transformations. The move towards upstream
engagement promised the introduction of lay expertise
into issues of scientific governance and research agenda-
setting. This move was a reaction against the drawbacks
of programmes directed at improving public understand-
ing of science, which have been described as a “false
dawn” [18] where sponsor interests dominate dialogues.
Watermeyer introduces the idea of the ‘polylogue’ in place
of ‘dialogue’, which is facilitated by the use of online activ-
ities in public engagement [19]. The polylogue differs from
the dialogue in that it not only multiplies the number of
conversationalists, but also the number of conversations
occurring and regenerating at any one time. Thus Web 2.0
may appear to offer a deeper sense of the democratization
of science [20]. Another advantage of the polylogue is that
it “follows more faithfully the pursuit of the scientist in
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asking new questions, rather than the policy maker in
demanding new solutions” [18]. It also has associated risks,
however. An over-abundance of subjective points of view
create radical uncertainty, and introduces uninvited con-
versations into public policy debates. Wikipedia has dem-
onstrated the added problem of crowd sourcing, and its
production of (questionable) knowledge claims.
Another dimension of citizenry is that patients network
to make research endeavors their own. Organizations in
the U.S. such as Genetic Alliance [21], PatientsLikeMe
[22] and the Patient-Centered Outcomes Research
Institute [23] serve as examples. Another example is the
Personal Genome Project [24], where individuals can put
their whole genome on the web. The willingness to pub-
licly share personal (phenotype; socio-demographic etc.)
and genetic health data on the web, or to be contacted by
researchers for possible inclusion in trials typifies this
movement. Patient groups are concerned with a more effi-
cient translation of research into the clinic—an expanding
area of research in its own right. What are the challenges,
barriers and bottlenecks that impede the process of trans-
lation? These include ethical challenges in addition to en-
suring adequate resources and preparedness of personnel.
Transparency
Transparency refers to the ways in which activities are
carried out openly. Patient information is accessible not
only to interested parties, but also to the public at large.
Based on recent figures from the Transparency Initiative
first launched by the European Medicines Agency, a
proactive clinical trial data sharing policy was proposed
[25]. Furthermore, the work of the All Trials petition
[26] and GlaxoSmithKline [27] led to a portal for anon-
ymized data release for clinical trials, and are both indi-
cative of greater access to industry data. Today, such
available data includes completed clinical trials whether
published or not and whether successful or not. The data
are, however, limited to the scope/disease of the original
consent even when anonymized. As of September 2014,
10 companies are listed as users of the system. Of the 119
research proposals submitted to the website between May
7th, 2013 and March 31st, 2015, 83 were approved or
approved with conditions [28].
Research proposals are checked to make sure the in-
formation is complete and that they meet the informed
consent requirements of this initiative and of the spon-
sor. They are then sent to the Independent Review Panel.
Panel members receive a brief research proposal including
analysis and publication plans once it has been processed
for scientific credibility. The Panel accepts or rejects
proposals based on scientific merit, researcher qualifica-
tions and management of conflicts of interest. In early
2015, the Institute of Medicine (IOM) lent its support to
data sharing in clinical trials [29]. The IOM called for a
multi-stakeholder effort to foster a culture of responsible
data sharing, with a focus on improved infrastructure,
technology, operational management, and funding.
Right not to know
Access to information is not always empowering. While
the argument for a ‘right not to know’ is not in itself
new, it is being deployed in novel ways. There has been
a tsunami of data (still mostly indecipherable) with the
arrival of next generation sequencing technologies
(NGS). Due to the very nature of NGS, the data revealed
are often beyond the research objectives. Secondary,
rather than incidental findings may be a better term for
such data as a result [30, 31]. Indeed, we posit that in
the near future more emphasis may well be placed on
asking individuals what they do not wish to know when
they consent to research or diagnoses that utilize NGS.
There continues to be discussion about how a right
not to know should be conceptualized. Graeme Laurie
in the second edition of The Right to Know and the Right
not to Know, argues that while autonomy underpins the
right to know, the interests at stake in the right not to
know are best construed as privacy interests, except
where an individual has expressed a prior wish not to
know [32]. The right not to know finds its ‘genetic’ ori-
gins in the Human Genome project, and is enshrined in
two international documents adopted in 1997 by UNESCO
[2] and the Council of Europe [33]. The right not to know
has only recently appeared in two U.S. policies that
recognize its legitimacy in genetic disclosure [30]. Although
both documents contoured the right not to know, there are
particular contexts where this right requires immediate fur-
ther delineation, namely in pediatrics. The international
pediatric platform of the Public Population Project in Gen-
omics, for example, recommends that parents not be
allowed to exercise their right not to know when the
findings reveal a clinically significant condition that is
treatable or preventable during childhood [34].
Globalization
In this article we are concerned not so much with
globalization as an economic and political phenomenon,
but with the global dimensions of ethics. When we refer to
the ways in which ethical issues are global we mean one of
two things: either that issues have a global reach (for ex-
ample foreign aid, where actions taken in one part of the
globe impact another) or that they are global in themselves
(such as climate change or pandemics). In the past 10 years,
the global dimension of issues in genomics has become
more important. Speaking of the human genome as the
common heritage of humanity, even in a symbolic sense,
suggests genomics is global at the level of the genome. Spe-
cific issues in the first sense are now more central, namely
the transfer of samples and data across borders. Data
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sharing between different biobanks is necessary in order to
achieve sufficient statistical power to underpin significant
results [35]. This development clearly challenges the prin-
ciples discussed above, notably privacy and security but
also accentuates the procedural inefficiencies of research
ethics review. If research is increasingly global, a system for
mutual recognition of substantial equivalency of ethics re-
view and of oversight in different jurisdictions is key for
collaborative science generally, but genomics and multi-
centred clinical trials specifically [36]. Concerns about
whether samples can be appropriately protected in differ-
ent jurisdictions raises questions about the possibility of
ethics review harmonization. In other words, is there
enough commonality as to the governance mechanisms
needed for review? The GA4GH is moving towards meet-
ing this challenge.
Summary
We posit there is a movement towards emphasizing gov-
ernance, security, empowerment, transparency, the right
not to know and globalization in the contemporary
ethics of genome medicine. Recently, this phenomenon of
“ethical-globalization” motivated a more politically action-
able human rights approach to the above areas as demon-
strated in the data sharing Framework of the GA4GH and
others. International interoperability and harmonization
promote and facilitate the principles we describe, but there
is no doubt that more profound structural changes are
required to buttress and realize these principles. Clear sys-
tems of governance, public trust in data security, personal
empowerment and the responsibility it brings re “knowing”
(or not) as well as transparency of research outcomes are to
be welcomed. The human rights of all citizens to benefit
from scientific advances, and of scientists to be recognized
for their contributions will only become truly actionable if
they underpin the very raison d’être of responsible science.
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